| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL REVIEW |
Department of Nutrition and Food Science (A.D., C.B.H.), San Jose State University, San Jose, California 95192-0058; and Department of Vascular Surgery (P.L.W.H.), Veterans Affairs Medical Center, San Francisco, California 94121-1598
Address all correspondence and requests for reprints to: Clarie B. Hollenbeck, Ph.D., Department of Nutrition and Food Science, San Jose State University, One Washington Square, San Jose, California 95192-0058. E-mail: clariebh{at}casa.sjsu.edu.
Context: The purpose of this review was to critically evaluate current research on the effect of soy protein and isoflavone supplements on plasma lipoproteins and place the potential role of soy in the prevention of coronary artery disease (CAD) into a clinical perspective.
Evidence Acquisition: An extensive literature search was performed using a variety of medical and scientific databases including Medline, PubMed, Science Direct, Ovid, NIST, and Infotrac to identify relevant articles. Journal articles were cross-referenced for additional sources of information. Articles were evaluated based on level of experimental control as well as statistical, quantitative, and clinical analysis.
Evidence Synthesis: Soy and soy isoflavones have been the object of extensive research investigating their potential hypocholesterolemic effects and possible role in the prevention of CAD. It has been suggested that soy, especially the isoflavones contained in soy, improves lipoprotein levels, thus reducing the risk for CAD. This belief, however, is not uniformly accepted. Moreover, the experimental evidence in support of this notion is not as overwhelming as generally perceived, and the current available data reveal that the discrepancies observed are primarily statistical in nature rather than reflecting actual quantitative differences in the hypocholesterolemic effects detected.
Conclusions: A critical analysis of the investigations to date indicates the data are not quantitatively impressive and raises substantial questions about the clinical importance of the hypocholesterolemic effects observed.
This article has been cited by other articles:
![]() |
A. A Thorp, P. R. Howe, T. A Mori, A. M Coates, J. D Buckley, J. Hodgson, J. Mansour, and B. J Meyer Soy food consumption does not lower LDL cholesterol in either equol or nonequol producers Am. J. Clinical Nutrition, August 1, 2008; 88(2): 298 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M Steinberg Soybeans or soymilk: does it make a difference for cardiovascular protection? Does it even matter? Am. J. Clinical Nutrition, April 1, 2007; 85(4): 927 - 928. [Full Text] [PDF] |
||||
![]() |
N. R Matthan, S. M Jalbert, L. M Ausman, J. T Kuvin, R. H Karas, and A. H Lichtenstein Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects Am. J. Clinical Nutrition, April 1, 2007; 85(4): 960 - 966. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |